Processa Pharmaceuticals, Inc. 8-K

What Happened
Processa Pharmaceuticals filed a Form 8-K on April 30, 2026, reporting that Dr. Sian Bigora, the Company’s Chief Development and Regulatory Officer, will move from a full‑time executive officer role to a part‑time employee position as part of a planned transition toward retirement. The change is effective May 1, 2026; her existing full‑time employment agreement will terminate and be replaced by a new part‑time arrangement. Dr. Bigora will retain her title and continue to provide services in a reduced capacity.

Key Details

• Filing date: April 30, 2026; change effective: May 1, 2026.
• Dr. Sian Bigora will no longer be designated an “executive officer” for purposes of Section 16 of the Exchange Act.
• Her full‑time employment agreement will terminate and be replaced by a part‑time employment arrangement effective May 1, 2026.
• She will keep any previously granted equity awards (subject to plan terms) and remain eligible for previously awarded bonus compensation per original terms.

Why It Matters
This is an executive leadership transition rather than a departure: Dr. Bigora remains with the company in a reduced role and retains equity and prior bonus eligibility. For investors, the filing changes Section 16 reporting status (less frequent executive disclosures) and signals a gradual shift in day‑to‑day executive responsibilities as she moves toward retirement. Monitor future filings for any announcements about successors, additional role changes, or impacts to development and regulatory operations.